126 related articles for article (PubMed ID: 17107281)
1. Experimental therapy in myelofibrosis with myeloid metaplasia.
Verstovsek S; Quintás-Cardama A; Kantarjian H; Tefferi A
Expert Opin Investig Drugs; 2006 Dec; 15(12):1555-63. PubMed ID: 17107281
[TBL] [Abstract][Full Text] [Related]
2. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Mesa RA; Quintás-Cardama A; Verstovsek S
Curr Hematol Malig Rep; 2007 Feb; 2(1):25-33. PubMed ID: 20425385
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of myelofibrosis with myeloid metaplasia.
Tefferi A
J Clin Oncol; 2005 Nov; 23(33):8520-30. PubMed ID: 16293880
[TBL] [Abstract][Full Text] [Related]
4. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Mesa RA; Tefferi A; Lasho TS; Loegering D; McClure RF; Powell HL; Dai NT; Steensma DP; Kaufmann SH
Leukemia; 2006 Oct; 20(10):1800-8. PubMed ID: 16871275
[TBL] [Abstract][Full Text] [Related]
6. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Arora B; Mesa R; Tefferi A
Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
[TBL] [Abstract][Full Text] [Related]
8. The therapy of myelofibrosis: targeting pathogenesis.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
10. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
[TBL] [Abstract][Full Text] [Related]
11. Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Odenike O; Tefferi A
Semin Oncol; 2005 Aug; 32(4):422-31. PubMed ID: 16202688
[TBL] [Abstract][Full Text] [Related]
12. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
13. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
14. New insights into the pathogenesis and drug treatment of myelofibrosis.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
[TBL] [Abstract][Full Text] [Related]
15. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
[TBL] [Abstract][Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions: Myelofibrosis.
Pettit K; Verstovsek S; Talpaz M
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):191-199. PubMed ID: 30987952
[TBL] [Abstract][Full Text] [Related]
17. New approaches in the treatment of myelofibrosis.
Hennessy BT; Thomas DA; Giles FJ; Kantarjian H; Verstovsek S
Cancer; 2005 Jan; 103(1):32-43. PubMed ID: 15565565
[TBL] [Abstract][Full Text] [Related]
18. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
Hogan WJ; Litzow MR; Tefferi A
Curr Hematol Malig Rep; 2007 Feb; 2(1):34-42. PubMed ID: 20425386
[TBL] [Abstract][Full Text] [Related]
20. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]